Across the two RECONNECT Phase 3 trials in 1,267 premenopausal women with hypoactive sexual desire disorder, desire scores rose 0.30 and 0.42 above placebo over 24 weeks.
Kingsberg SA et al., Obstet Gynecol 2019Free shipping over €250 · Tracked, discreet delivery in Europe
premium-grade research peptides
PT-14110 mg
Melanocortin receptor agonist, studied for libido and sexual response. Research compound. Lyophilized powder for reconstitution.
Lyophilized peptide · single vial
What it is
PT-141 is bremelanotide, a synthetic cyclic heptapeptide and an active metabolite of the melanocortin analogue Melanotan II. It is a non-selective melanocortin receptor agonist with activity at MC1R, MC3R and MC4R. It appears in sexual medicine research, where it has been through two Phase 3 trials in premenopausal women with hypoactive sexual desire disorder.
- Class
- Sexual Wellness
- Formula
- PT-141 · 10 mg
- Format
- Lyophilized powder
How it works
PT-141 (bremelanotide) is a melanocortin receptor agonist studied in libido and sexual response research.
MC4R
Acts in the brain
PT-141 activates melanocortin-4 receptors in the central nervous system rather than acting on blood flow.
Desire
A central pathway
Research frames the compound as acting on desire itself, upstream of the vascular mechanisms other agents target.
Clinical
Studied in trials
Bremelanotide has been examined in clinical trials for sexual response in both male and female subjects.
Key benefits
- Melanocortin research focused on libido and sexual response.
- Protocols studying desire and arousal in both men and women.
- Studied as a centrally acting option, not a vascular one.
Laboratory research only. Not for human or veterinary use.
What published research is studying
Human clinical data- Sexual desire and desire-related distress in premenopausal women with hypoactive sexual desire disorder (two Phase 3 trials)
- Durability of response and adverse events across an open-label extension
- Subjective arousal and desire in premenopausal women with female sexual arousal disorder
- Erectile response in men who did not respond to a PDE5 inhibitor
Human evidence is substantial for the female desire indication, with two randomised placebo-controlled Phase 3 trials and an open-label extension. Average effect sizes on desire scales were modest.
Key research findings and references
Key research findings
In the same trials, desire-related distress fell relative to placebo by 0.37 in study 301 (P<.001) and 0.29 in study 302 (P=.005). Nausea, flushing and headache were each reported by 10% or more.
Kingsberg SA et al., Obstet Gynecol 2019In the open-label extension, 684 participants continued and 272 completed it, with change in the Female Sexual Function Index desire domain from baseline ranging from 1.25 to 1.30.
Simon JA et al., Obstet Gynecol 2019In a randomized study of 342 men who had not responded to sildenafil, 33.5% of the bremelanotide group met the response criterion versus 8.5% on placebo (P=0.03).
Safarinejad MR, Hosseini SY, J Urol 2008Published study duration
- RECONNECT Phase 3 trials: a 4-week qualification period, a 4-week baseline period, then 24 weeks of double-blind treatment (NCT02333071).
- Open-label extension: continued after the 24-week core phase in 684 participants (Simon et al. 2019).
- Female sexual arousal disorder study: a double-blind crossover with laboratory sessions in 18 participants (Diamond et al. 2006).
Research endpoints
- Female Sexual Function Index desire domain score
- Female Sexual Distress Scale item on being bothered by low desire
- Erectile-function response rate in the sildenafil non-responder study
- Reported adverse events including nausea and flushing
- Vaginal photoplethysmography response in the arousal study
References
- Kingsberg SA et al., Obstet Gynecol 2019. Bremelanotide for hypoactive sexual desire disorder, two randomized Phase 3 trials
- Simon JA et al., Obstet Gynecol 2019. Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder
- RECONNECT Study 301, ClinicalTrials.gov. Phase 3 randomized placebo-controlled trial of bremelanotide in premenopausal women with HSDD
- Diamond LE et al., J Sex Med 2006. Effect of bremelanotide (PT-141) on subjective sexual response in premenopausal women with sexual arousal disorder
- Safarinejad MR, Hosseini SY, J Urol 2008. Salvage of sildenafil failures with bremelanotide, a randomized placebo-controlled study
- Dhillon S et al., Drugs 2019. Bremelanotide, first approval
Summaries of published research, for context only. Research use only. Not for human or veterinary use.
premium-grade research peptides
PT-14110 mg
Melanocortin receptor agonist, studied for libido and sexual response. Research compound. Lyophilized powder for reconstitution.
Choose your vial
Choose strength
Quantity
1 vial
Add 2 more, save 5%
1 × PT-141 · 10 mg€65 / vial
€65
Free1 × 3 ml bacteriostatic water · 10 × 0.5 ml syringes · 10 × alcohol swabs · uu.life research handling card
- €185 to free shipping
- Ships in 1-2 business days
- Discreet EU
What you get
- 1 × PT-141 · 10 mg
Medical supply kitFreeOne kit with every vial1 × 3 ml bacteriostatic water10 × 0.5 ml syringes10 × alcohol swabs- uu.life research handling card
One supply kit ships with every vial: the counts above follow the quantity.
Optional spare suppliesHow To Use The Vials
The standard supplies above ship free with every vial. Add extras only if the research plan needs more.
Independently lab tested
99%+ purity standard
Identity verified by LC-MS
Batch COA available
Tracked delivery to European Union
Research handling
Full handling guide- 01
Lyophilized, sealed, batch-numbered
Each vial ships as a freeze-dried powder under an inert seal, tied to the batch on its Certificate of Analysis.
- 02
Store cold and dark
Unopened vials are kept refrigerated at 2-8°C away from light. Reconstituted material is stored refrigerated and used within the window the research plan defines.
- 03
Reconstitute with bacteriostatic water
The included bacteriostatic water is added slowly down the vial wall and the vial is swirled, never shaken.
- 04
Research use only
Supplied for laboratory research. Not for human or veterinary use. Handle with the personal protective equipment the laboratory requires.
Before you order
What ships in the box?
The vials selected, plus a free supply kit with every vial: one 3 ml bacteriostatic water, ten 0.5 ml syringes and ten alcohol swabs per vial, and the uu.life research handling card.
How does volume pricing work?
The price per vial depends on how many vials of the same strength are on the line. 3-4 vials take 5% off, 5 or more take 10% off. The discount is applied automatically and shows on the product page, in the cart and at checkout.
Is every batch tested?
Yes. Every batch is tested by an independent laboratory for identity and purity, and the Certificate of Analysis is linked from this page and the lab-testing library.
How fast is delivery?
Orders are typically dispatched within 1-2 business days and arrive across most of Europe in 3-5 business days, tracked, in discreet packaging. Orders over €250 ship free, and Shipping Protection can be added at checkout.
Is this for human use?
No. Every product is sold for laboratory research only and is not for human or veterinary use.
Ready to order PT-141?
Choose a strength and quantity above. Volume pricing applies automatically.
Quality you can trace.
Batch-tested purity
Every vial ships with a Certificate of Analysis from an independent third-party lab. No exceptions.
Fast shipping
Orders are typically dispatched within 1-2 business days. Most European deliveries arrive in 3-5 business days.
Replacement guarantee
Arrived damaged? Send photos and the order number and a replacement is arranged.
